Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





p-DICHLOROBENZENE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 106-46-7; **Chemical Formula:** C6H4Cl2
OSHA formerly had an 8-hour TWA limit of 75 ppm for p-dichlorobenzene. The ACGIH has a limit of 75 ppm TWA and a STEL of 110 ppm for this white crystalline material, which has a camphor-like odor. The ACGIH’s limit recognizes that the para isomer is somewhat less toxic than the ortho isomer, for which the ACGIH has established a ceiling limit of 50 ppm. The proposed PEL retained the 75-ppm TWA limit and added a STEL of 110 ppm; the final rule establishes these limits.
In animal studies, an injection of 0.005 gram of p-dichlorobenzene in rats caused slight liver necrosis (Cameron, Thomas, Ashmore et al. 1937/Ex. 1-471). The intraperitoneal injection LD(50) for rats has been reported as 2562 mg/kg (Zupko and Edwards 1949/Ex. 1-878). The oral LD(50) in mice is 2950 mg/kg (Domenjoz 1946, as cited in ACGIH 1986/Ex. 1-3, p. 179); for rats, the oral LD(50) is 2512 mg/kg (Varshavskaya 1970, as cited in ACGIH 1986/Ex. 1-3, p. 179). Rabbits fed a daily dietary exposure of 5 grams developed opacity of the lens in 3 weeks (Berliner 1939/Ex. 1-715); this finding was not confirmed, however, in repeated studies (Pike 1944/Ex. 1-656).
Reports of a human inhalation exposure to unspecified levels of p-dichlorobenzene describe swelling of the feet, ankles, and hands after day-long use of a mothproofing agent consisting of this substance (Clayton 1935/Ex. 1-306). Other reports describe cataracts caused by exposure to unspecified concentrations of the vapor of p-dichlorobenzene (Berliner 1939/Ex. 1-715). Petit and Champaix (1948, as cited in ACGIH 1986/Ex. 1-3, p. 179) report the case of a woman who experienced tingling of the hands, vertigo, and loss of weight from working for 18 months with a mixture of 90 parts p-dichlorobenzene and 10 parts hexachloroethane (airborne concentration not specified).
OSHA received three comments on p-dichlorobenzene: from NIOSH (Ex. 8-47), the Workers Institute of Safety and Health (WISH) (Ex. 116), and the Halogenated Solvents Industry Alliance (HSIA) (Ex. 186). WISH simply pointed out that the ACGIH Documentation (1986/Ex. 1-3) entry for this substance includes fewer, and different, references from those relied on by the Agency for Toxic Substances and Disease Registry (Ex. 116, Table 1), without further comment. The HSIA (Ex. 186, App. D) submitted a letter from EPA’s Science Advisory Board to Lee Thomas, Administrator of EPA (3/9/88). The letter points out that there is a scientific hypothesis to the effect that, for many halogenated organics (including p-dichlorobenzene), the mechanism causing tumors in rats exposed to these substances may not be operative in humans (Ex. 186D). According to the HSIA, this hypothesis may have “important implications for human health risk assessment” (Ex. 186D, p. 2). On the other hand, NIOSH (Ex. 8-47, Table N6B) interprets the evidence for p-dichlorobenzene to mean that it is a potential human carcinogen that deserves full Section 6(b) rulemaking. OSHA will consider NIOSH’s recommendation in light of the Agency’s rulemaking priorities.
In the final rule, OSHA is retaining the 8-hour TWA PEL of 75 ppm TWA and adding a STEL of 110 ppm for p-dichlorobenzene. The Agency concludes that both a TWA and a STEL are necessary to protect workers from the significant risk of eye damage, vertigo, and neuropathic effects, which constitute material impairments of health that are associated with occupational exposure to p-dichlorobenzene at levels above the 8-hour TWA PEL.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue